3,205 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Genesis Private Wealth LLC

Genesis Private Wealth LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,205 shares of the company’s stock, valued at approximately $210,000.

A number of other hedge funds also recently made changes to their positions in the business. Bank of Montreal Can grew its stake in AstraZeneca by 109.6% in the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after buying an additional 1,605,758 shares during the last quarter. Franklin Resources Inc. grew its position in shares of AstraZeneca by 8.7% in the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after purchasing an additional 1,522,715 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of AstraZeneca during the third quarter worth approximately $72,437,000. Fisher Asset Management LLC lifted its holdings in AstraZeneca by 5.3% during the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after purchasing an additional 524,175 shares during the last quarter. Finally, AXA S.A. boosted its stake in AstraZeneca by 1,039.6% in the 2nd quarter. AXA S.A. now owns 400,242 shares of the company’s stock valued at $31,215,000 after purchasing an additional 365,121 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Price Performance

AZN stock opened at $68.20 on Thursday. The company’s 50-day moving average price is $66.20 and its two-hundred day moving average price is $74.32. The firm has a market cap of $211.49 billion, a P/E ratio of 32.63, a P/E/G ratio of 1.13 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the business earned $0.87 earnings per share. The company’s revenue was up 18.0% on a year-over-year basis. On average, analysts anticipate that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.